Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Immuneering (Nasdaq: IMRX) said CEO Ben Zeskind will speak in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 3:45 p.m. ET.
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) said CEO Ben Zeskind will speak in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 3:45 p.m. ET. The session will be webcast live and archived in the company's Investor Relations Events & Presentations section.
Positive
- None.
Negative
- None.
Details
News Market Reaction – IMRX
In the Apr 7 session, IMRX declined 3.15%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Current price
- $5.45
- Pre-news trading level on article date
- 52-week range
- $1.10–$10.08
- Price range over the last 52 weeks
- Shelf registration amount
- $300,000,000
- Form S-3 universal shelf filed Aug 13, 2025
- ATM capacity
- $100,000,000
- Equity distribution agreement under S-3 shelf
- 12‑month OS
- 64%
- Phase 2a atebimetinib + mGnP in first-line pancreatic cancer
- Year-end cash
- $217.0M
- Cash, cash equivalents and marketable securities at end of 2025
- 2025 net loss
- $56.0M
- Full-year 2025 net loss from operations
- Q4 2025 net loss
- $11.6M
- Fourth-quarter 2025 net loss reported in 8-K
Historical Context
-
Planned AACR molecular data on atebimetinib-treated RAS-mutant solid tumor patients.
-
Q4/FY 2025 results, 64% 12‑month OS, strong cash and Phase 3 timeline.
-
Leerink Global Healthcare Conference fireside chat and 1x1 investor meetings.
-
Oppenheimer virtual conference company presentation and investor meetings.
-
Updated Phase 2a pancreatic cancer data with 64% 12‑month OS and strong efficacy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that Ben Zeskind, Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 3:45 p.m. ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering
Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. The company expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and early-stage programs. For more information, please visit www.immuneering.com.
Investor Contact:
Courtney Dugan
Cdugan@immuneering.com
Media Contact:
Gina Nugent
Gina.nugent.external@immuneering.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.